Chapple C - Search Results

1

The development of the ICIQ-UAB: A patient reported outcome measure for underactive bladder.

Uren AD, Cotterill N, Harding C, Hillary C, Chapple C, Lasch K, Stroupe A, Deshpande C, Delbecque L, Van Koeveringe G, Oelke M, Belal M, Bosch R, Blok B, Nitti V, Gotoh M, Takei M, Crawford B, Klaver M, Bongaerts D, Hakimi Z, Kos T, Abrams P. Uren AD, et al. Among authors: chapple c. Neurourol Urodyn. 2019 Mar;38(3):996-1004. doi: 10.1002/nau.23947. Epub 2019 Feb 22. Neurourol Urodyn. 2019. PMID: 30801826

2

Definition of normality of pressure-flow parameters based on observations in asymptomatic men.

Rosario DJ, Woo HH, Chapple CR. Rosario DJ, et al. Neurourol Urodyn. 2008;27(5):388-94. doi: 10.1002/nau.20537. Neurourol Urodyn. 2008. PMID: 18064668

3

Lower urinary tract symptoms revisited: a broader clinical perspective.

Chapple CR, Wein AJ, Abrams P, Dmochowski RR, Giuliano F, Kaplan SA, McVary KT, Roehrborn CG. Chapple CR, et al. Eur Urol. 2008 Sep;54(3):563-9. doi: 10.1016/j.eururo.2008.03.109. Epub 2008 Apr 8. Eur Urol. 2008. PMID: 18423969 Review.

4

The β3-adrenoceptor mediates the inhibitory effects of β-adrenoceptor agonists via the urothelium in pig bladder dome.

Masunaga K, Chapple CR, McKay NG, Yoshida M, Sellers DJ. Masunaga K, et al. Neurourol Urodyn. 2010 Sep;29(7):1320-5. doi: 10.1002/nau.20838. Neurourol Urodyn. 2010. PMID: 20151470

5

Efficacy and safety of tolterodine extended-release in men with overactive bladder symptoms treated with an α-blocker: effect of baseline prostate-specific antigen concentration.

Chapple CR, Herschorn S, Abrams P, Wang JT, Brodsky M, Guan Z. Chapple CR, et al. BJU Int. 2010 Nov;106(9):1332-8. doi: 10.1111/j.1464-410X.2010.09359.x. BJU Int. 2010. PMID: 20497416 Clinical Trial.

6

Validation of the urinary sensation scale (USS).

Coyne KS, Margolis MK, Hsieh R, Vats V, Chapple CR. Coyne KS, et al. Neurourol Urodyn. 2011 Mar;30(3):360-5. doi: 10.1002/nau.21005. Epub 2011 Jan 20. Neurourol Urodyn. 2011. PMID: 21254195

7

Defining a patient-reported outcome measure for urethral stricture surgery.

Jackson MJ, Sciberras J, Mangera A, Brett A, Watkin N, N'dow JM, Chapple CR, Andrich DE, Pickard RS, Mundy AR. Jackson MJ, et al. Eur Urol. 2011 Jul;60(1):60-8. doi: 10.1016/j.eururo.2011.03.003. Epub 2011 Mar 17. Eur Urol. 2011. PMID: 21419566

8

Urinary urgency: a review of its assessment as the key symptom of the overactive bladder syndrome.

Abrams P, Chapple CR, Jünemann KP, Sharpe S. Abrams P, et al. World J Urol. 2012 Jun;30(3):385-92. doi: 10.1007/s00345-011-0742-8. Epub 2011 Aug 19. World J Urol. 2012. PMID: 21853323 Review.

9

A proof-of-concept study: mirabegron, a new therapy for overactive bladder.

Chapple CR, Amarenco G, López Aramburu MA, Everaert K, Liehne J, Lucas M, Vik V, Ridder A, Snijder R, Yamaguchi O; BLOSSOM Investigator Group. Chapple CR, et al. Neurourol Urodyn. 2013 Nov;32(8):1116-22. doi: 10.1002/nau.22373. Epub 2013 Feb 19. Neurourol Urodyn. 2013. PMID: 23424164 Clinical Trial.

10

A prospective patient-centred evaluation of urethroplasty for anterior urethral stricture using a validated patient-reported outcome measure.

Jackson MJ, Chaudhury I, Mangera A, Brett A, Watkin N, Chapple CR, Andrich DE, Pickard RS, Mundy AR. Jackson MJ, et al. Eur Urol. 2013 Nov;64(5):777-82. doi: 10.1016/j.eururo.2013.04.037. Epub 2013 May 1. Eur Urol. 2013. PMID: 23664422

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

928 results

Search Page